leupaxin Antibody (F-12): sc-376903

Leupaxin Antibody (F-12) is a mouse monoclonal IgG3 antibody that detects leupaxin in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Leupaxin, also known as LDPL or LPXN, is a 386 amino acid cytoplasmic protein belonging to the paxillin family, characterized by four leucine-rich LD-motifs at the N-terminus and four LIM domains at the C-terminus. Leupaxin is predominantly expressed in lymphoid tissues, including the spleen, lymph nodes, thymus, and appendix, while exhibiting lower levels in bone marrow and fetal liver. The structural composition of leupaxin facilitates interaction with focal adhesion kinase family member PYK2, forming a complex that plays a significant role in cell type-specific signaling and regulation at adhesion sites. Leupaxin serves as a substrate for tyrosine kinases in lymphoid cells, indicating involvement in tyrosine kinase-mediated signaling pathways. Additionally, leupaxin has been identified as a potential progression marker for certain subsets of prostate cancer and may function as a novel coactivator of the androgen receptor, highlighting importance in cancer biology and therapeutic targeting.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

leupaxin Antibody (F-12) References:

1. Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast.  |  Gupta, A., et al. 2003. J Bone Miner Res. 18: 669-85. PMID: 12674328
2. Leupaxin negatively regulates B cell receptor signaling.  |  Chew, V. and Lam, KP. 2007. J Biol Chem. 282: 27181-27191. PMID: 17640867
3. Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells.  |  Kaulfuss, S., et al. 2008. Mol Endocrinol. 22: 1606-21. PMID: 18451096
4. Leupaxin is similar to paxillin in focal adhesion targeting and tyrosine phosphorylation but has distinct roles in cell adhesion and spreading.  |  Chen, PW. and Kroog, GS. 2010. Cell Adh Migr. 4: 527-40. PMID: 20543562
5. Leupaxin stimulates adhesion and migration of prostate cancer cells through modulation of the phosphorylation status of the actin-binding protein caldesmon.  |  Dierks, S., et al. 2015. Oncotarget. 6: 13591-606. PMID: 26079947
6. Regulation of β-catenin transcription activity by leupaxin in hepatocellular carcinoma.  |  Shi, J., et al. 2016. Tumour Biol. 37: 2313-20. PMID: 26361959
7. Structural Basis for the Interaction between Pyk2-FAT Domain and Leupaxin LD Repeats.  |  Vanarotti, MS., et al. 2016. Biochemistry. 55: 1332-45. PMID: 26866573
8. Leupaxin Promotes Bladder Cancer Proliferation, Metastasis, and Angiogenesis Through the PI3K/AKT Pathway.  |  Hou, T., et al. 2018. Cell Physiol Biochem. 47: 2250-2260. PMID: 29975926
9. Leupaxin promotes hepatic gluconeogenesis and glucose metabolism by coactivation with hepatic nuclear factor 4α.  |  Luo, X., et al. 2025. Mol Metab. 91: 102075. PMID: 39603504
10. Leupaxin is a novel LIM domain protein that forms a complex with PYK2.  |  Lipsky, BP., et al. 1998. J Biol Chem. 273: 11709-13. PMID: 9565592

The preferred leupaxin antibody is leupaxin Antibody (B-2): sc-376820.